Alfacell Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced that the U.S.
Alfacell Drug Designated Orphan Product
Alfacell Corporation has said that the FDA has granted orphan-drug for its lead drug candidate, Onconase for treatment of malignant mesothelioma. Alfacell is evaluating Onconase in a confirmatory phase IIIb clinical trial in unresectable malignant mesothelioma.
Alfacell Shares Rise on FDA Designation
Shares of Alfacell Corp. soared Tuesday after the company said federal regulators gave it exclusive rights to market its Onconase cancer drug for seven years, assuming the drug is approved.
A soul-baring moment for Quartetto Gelato
Acclaimed group to perform locally despite recent death of a member Musical chamber ensembles are by their nature intimate: Members are bound together by a love for and devotion to the performance of hand-selected repertoire, and often by relationships of blood or marriage. The musical personality of the group is shaped by the eccentricities and histories of each member.